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There is no question that biobanks have 
become essential in clinical research. Clini-
cians and researchers alike recognize that 
patient-tailored precision medicine can only 
be performed after large-scale investigation 
of well-powered datasets, in which data from 
complex, multifactorial diseases have been 
meticulously defined [1]. In order to collect 
biomaterial and data from sufficient subjects 
and/or patients, many biobanks are now 
multi-institutional or even multinational. 
This comes with specific issues, mainly con-
cerning definitions and standardization, but 
also diversity in ethics and regulations.
Biobank
First off, what constitutes a biobank? The 
most conventional definition is a collec-
tion of biomaterial plus associated clinical 
data [2]. The biomaterial can be any material 
collected from a subject, but most often con-
sists of blood and/or DNA, and sometimes 
tissue from a diseased site such as a tumor. 
For the sake of this editorial we only discuss 
human biobanks, but biobanks can also be 
derived from experimental animal studies, or 
even cell lines. Biobanks can be population-
based or may be disease-specific [3]. In short, 
population biobanks are large, organized, 
searchable repositories that are national or 
international in scope. Over a number of 
years, these collections aim to follow a cohort 
of individuals to assess the impact of a variety 
of factors (e.g., income, lifestyle and environ-
ment) on disease status and their progression. 
Disease-specific biobanks have the advantage 
of offering insight into the genetic basis of 
rare conditions as well as that of more com-
mon diseases [3]. For most of this editorial we 
will focus on disease-specific biobanks.
Biomaterial
The biomaterial and its procurement, preser-
vation and analysis have to be strictly defined 
and standardized, especially in multicenter 
and international biobanks. Not only does 
this standardization have to be defined 
a priori, but also a quality control system has 
to be in place to monitor the adherence to 
definitions and performance of the partici-
pating centers. Only by proper standardiza-
tion does the biobank contain sufficient 
and accurate data for further investigations. 
Whatever biomaterial is collected, it has to be 
related to the scientific purposes of the bio-
bank. A problem with this might come from 
the fact that often biobanks collect samples 
over many years and thus the material itself 
plus the standard operating procedures have 
to be defined in a time when the eventual use 
is not yet clear. In our own experience, the 
collection of tumor RNA from a large num-
ber of breast cancer patients over the years 
using a standard column-based isolation kit 
lead to a biobank that was not useful for 
the investigation of miRNAs, which could 
not have been envisioned at the start of the 
biobank. Techniques (e.g., nucleotide isola-
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tion kits and sequencing equipment) will improve over 
time. Therefore, predefined standard operating proce-
dures might be outdated, and the biobank will have to 
decide whether to upgrade and take advantage of new 
possibilities, or to adhere to the earlier protocols for the 
sake of standardization.
Availability of equipment and resources can also 
lead to unavoidable differences in protocols and qual-
ity of the biomaterials between participating institu-
tions and/or countries. Maintenance of consistent 
intersite processing can be challenging. In this case, 
centralization of the processing and/or storage of the 
collected biomaterial might be an option to consider. 
However, in studies where samples are shipped to a dif-
ferent location for processing, the time delay between 
collection and stabilization may lead to loss of some 
unstable markers [4]. Thus, depending on which type 
of variation is the most crucial for the biobank, a cen-
tral or a decentralized system (or a hybrid of these) 
should be attained.
Clinical data
Similarly, clinical data are in fact relevant personal and 
health information (which may include health records, 
family history, lifestyle and genetic information) from 
a patient that is relevant for the scientific purpose of 
the clinical biobank. A minimal dataset will have to 
be defined containing all possibly relevant informa-
tion. On the other hand, the items should be manage-
able and obtainable from most, if not all, contributing 
institutions. It is the hallmark of precision medicine 
for which this data are necessary. Only by collecting 
all relevant data and correlating this with outcome will 
future patient-tailored treatment be feasible.
Concerning intricacies in the collection of clini-
cal data especially relevant in international biobanks, 
special attention should be given to nomenclature and 
definitions: are all participants talking about the same 
thing? Strictly define your parameters. Collect as much 
raw data as possible; so, register dates of diagnosis, sur-
gery, start and end of treatment, recurrence and/or 
death, rather then asking the participants to report, 
for example, recurrence-free survival. Additionally, be 
aware of differences in standard treatment, follow-up 
features and interval, etc. A document should be in 
place defining all parameters and criteria, relevant for 
the biobank and its scientific purpose and as agreed 
upon by all participants [5].
An important matter of concern will be the vastly 
increasing amount of data, especially sequencing data. 
Information and communication technology solutions 
for data storage, with appropriate backup systems, 
should be accessible by all using a variety of systems, 
including in the future. For retrospective biobanks this 
can have the consequence that old paper-based patient 
files would have to be transferred to electronic systems. 
Even relatively current patient file systems might be 
incompatible with the scientific biobank data storage 
system, making the transfer of data challenging. This 
can be a costly aspect of a biobank, for which resources 
should be allocated beforehand.
Cost
Indeed, it is not only expensive to set up a biobank, 
but also to operate and maintain. For international 
biobanks, the cost of particular commercial kits (such 
as for DNA isolation, etc.) might be prohibitive for 
some institutions in low-income countries with poor 
research funding. However, even for well-funded 
organizations, funding for biobanks is often for a 
predefined period of time and purpose. Therefore, it 
is important for biobanks to adopt a business model 
in which both cost and revenue is considered. How-
ever, commercialization of the biobank biomaterial 
and/or clinical data is not always feasible, either due 
to national or institutional regulations, due to ethi-
cal guidelines and/or because subjects refuse in an 
informed consent.
Ethics
For all types of biobanks, an informed consent should 
be in place, and attention should be given to the 
patient’s right to withdraw, what to do with unsolicited 
findings, how to deal with privacy issues and whether 
commercialization is permitted, etc. [3]. A particular 
problem with decentralized international biobanks is 
the fact that ethical guidelines and the patient’s atti-
tude toward biobanks can differ widely between coun-
tries [6]. Initially, all ethical considerations should be 
in line with national guidelines in the country where 
the patient resides and the biomaterial is obtained. 
However, there is no global consensus regarding shar-
ing biomaterial and data. Eventually, consent will 
become ongoing and dynamic; participants will be 
able to engage as much as they choose and alter their 
consent choices over time [3].
Patient participation
It is important to realize that a patient or subject can 
play different roles in a biobank: not only as a donor, 
but also active in setting up the biobank; and help-
ing devise the informed consent, the scientific purpose 
“The biomaterial and its procurement, 
preservation and analysis have to be strictly 
defined and standardized, especially in 
multicenter and international biobanks.”
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and the publicity surrounding the biobank. A patient 
can have different questions concerning his disease 
compared with researchers. Also, they need to know 
biobanks exist and why they exist [6]. Most objec-
tions against biobanks are born out of mistrust in the 
objectives of such a biobank initiative, which might be 
thwarted by a strong and early patient participation in 
the above-mentioned aspects of the biobank.
Conclusion
Biobanks are crucial in many aspects of medical prac-
tice and research. However larger, multi-institutional or 
multinational initiatives are difficult to devise correctly. 
Start a biobank, but do it right: ‘There is no try.’
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